MIRA Pharmaceuticals, Inc.

MIRA Healthcare Drug Manufacturers General

In the quarter to June 2026, EPS grew 66.7% and free cash flow fell 50.8%, each against the same quarter a year earlier.

0.63 0.03 −4.55%
Market cap
$27.7M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(510.93%) (508.28%) (589.40%) (710.85%)
ROA
(477.58%) (456.59%) (577.42%) (684.27%)
ROIC
(32,898.61%) 0.00% 0.00% (12,016.10%)
Return on Tangible Assets
(378.18%) (308.99%) (336.78%) (381.90%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(0.28) (0.20) (0.10) (0.11)
Free Cash Flow
(5.33) (4.66) (4.23) (4.64)
Other line items

Show all line items

Columns are period end dates